Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.
Jérôme Fayette, MD, PhD
Advertisement
Articles by Jérôme Fayette, MD, PhD
Dr. Jérôme Fayette presents the findings of a phase 2 study (NCT03526835) assessing the overall response rate of petosemtamab in combination with pembrolizumab compared to pembrolizumab monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Advertisement
Latest Updated Articles
Dr Fayette on the Efficacy of Petosemtamab Plus Pembrolizumab in Metastatic HNSCCPublished: July 15th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5